 |
||
 |
 |
 |
| PGNX - (NASDAQ)
$7.90 - 0.68 |
May 17, 2012
4:00 PM ET |
Latest News
May 8, 2012
Progenics Pharmaceuticals Announces First Quarter 2012 Financial Results
May 4, 2012
Progenics Pharmaceuticals to Host Conference Call to Review First Quarter Financial Results on May 8
Apr 25, 2012
Salix and Progenics Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012
For the complete U.S. package insert for RELISTOR, please visit www.relistor.com 
Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions.
Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer.
Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness. Regulatory approval is pending for use of RELISTOR by patients with chronic, non-cancer pain. A phase 3 clinical trial of an oral formulation of methylnaltrexone completed enrollment in mid-2011.